According to Zacks, “Phreesia Inc. provides a patient intake management platform. The company’s SaaS platform engages patients in their care and provides a modern, consistent experience, while enabling healthcare organizations to optimize their staffing, boost profitability and enhance clinical care. Phreesia Inc. is based in New York. “
Several other research firms also recently commented on PHR. Cantor Fitzgerald started coverage on Phreesia in a research note on Wednesday, January 8th. They issued an overweight rating and a $32.00 price objective for the company. Raymond James assumed coverage on Phreesia in a research note on Thursday, December 19th. They issued an outperform rating and a $33.00 price objective for the company. KeyCorp assumed coverage on Phreesia in a research note on Thursday, January 30th. They issued an overweight rating and a $36.00 target price for the company. Finally, ValuEngine downgraded Phreesia from a buy rating to a hold rating in a research note on Thursday, October 31st. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $31.78.
Phreesia (NYSE:PHR) last posted its quarterly earnings data on Tuesday, December 10th. The company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. The firm had revenue of $32.80 million during the quarter, compared to analyst estimates of $29.48 million. Phreesia’s quarterly revenue was up 32.3% on a year-over-year basis. On average, equities research analysts expect that Phreesia will post -0.43 earnings per share for the current fiscal year.
In other news, Director Scott Perricelli sold 2,000,000 shares of the stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $24.48, for a total transaction of $48,960,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael Weintraub sold 10,680 shares of the stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $32.51, for a total value of $347,206.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,554,757 shares of company stock valued at $63,956,423.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PHR. TimesSquare Capital Management LLC purchased a new position in shares of Phreesia during the 3rd quarter worth $29,435,000. FMR LLC grew its holdings in shares of Phreesia by 116.2% during the 4th quarter. FMR LLC now owns 2,025,666 shares of the company’s stock worth $53,964,000 after purchasing an additional 1,088,782 shares during the period. Loomis Sayles & Co. L P purchased a new position in shares of Phreesia during the 4th quarter worth $16,629,000. Massachusetts Financial Services Co. MA purchased a new position in Phreesia during the 3rd quarter valued at about $11,955,000. Finally, Tamarack Advisers LP boosted its holdings in Phreesia by 230.0% during the 4th quarter. Tamarack Advisers LP now owns 660,000 shares of the company’s stock valued at $17,549,000 after acquiring an additional 460,000 shares during the period. Institutional investors and hedge funds own 51.49% of the company’s stock.
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.